Preparation and in vitro evaluation of synthetic high-density lipoproteins as parenteral drug delivery system for tamoxifen citrate
DOI:
https://doi.org/10.31351/vol32iss3pp105-117Keywords:
Tamoxifen citrate, breast cancer, bioinspired drug delivery system, synthetic high density lipoproteins, mimetic peptideAbstract
The aim of this study was to develop a bioinspired drug delivery system for tamoxifen citrate (TC) based on synthetic high density lipoproteins (sHDL). For this purpose, sHDL nanoparticles were prepared from a mimetic peptide (5A peptide) and different lipids using thin film hydration method followed by sonication and thermal cycling. Various formulation parameters including lipid composition, lipid to peptide ratio, and drug to carrier ratio had a remarkable impact on the properties and the release pattern of the nanoparticles. The optimized formula (F14) displayed a spherical morphology, average diameter of (35.7±12.4) nm, and a zeta potential (ζ) equals to (-48.4± 0.5) mV. The encapsulation efficiency and drug loading of F14 were (96.5±0.7%) and (9.65±0.1%), respectively. Besides, F14 showed a good stability in human plasma for 24 hours. The encapsulation of the lipophilic drug within the hydrophobic core of the nanocarrier enabled a slow drug release from nanoparticles which follows a near zero order controlled mechanism. The promising results of this study opens an avenue for using sHDL as a delivery system for administration of TC intravenously. Therefore, the optimized formula is suggested to be subject for future analyses in terms of in vitro cytotoxicity against breast cancer cells and in vivo evaluation in tumor bearing animals.
How to Cite
Publication Dates
References
Jahan S, Karim ME, Chowdhury EH. Nanoparticles targeting receptors on breast cancer for efficient delivery of chemotherapeutics. Biomedicines. 2021;9(2):1–30.
Higa G. Breast Cancer. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT, editors. Pharmacotherapy Principles & Practice. Fourth edi. New York: MC Graw Hill Education; 2016. p. 1321–2.
British Pharmacopoeia Commission. British Pharmacopoeia. London: The Stationery Office; 2009.
Mircioiu I, Anuta V, Ibrahim N, Mircioiu C. Dissolution of tamoxifen in biorelevant media. A two phase release model. Farmacia. 2012;60(3):315–24.
O’Neil M, editor. The Merck Index: An Encyclopedia of Chemicals,Drugs,and Biologicals. 14 th edit. New Jersey: merck; 2006.
Day CM, Hickey SM, Song Y, Plush SE, Garg S. Novel tamoxifen nanoformulations for improving breast cancer treatment: Old wine in new bottles. Molecules. 2020;25(5).
Schiff R, Chamness GC, Brown PH. Advances in breast cancer treatment and prevention: Preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). Breast Cancer Res. 2003;5(5):228–31.
British National Formulary (BNF). BMJ Group and the Royal Pharmaceutical Society of Great Britain; 2021. 997 p.
Ghaidaa S. Hameed, Methaq Hamad Sabar. Nano-carriers as a Selective Treatment for Cancer. Al Mustansiriyah J Pharm Sci. 2021;21(1):55–66.
Kuai R, Li D, Chen YE, Moon JJ, Schwendeman A. High-Density Lipoproteins: Nature’s Multifunctional Nanoparticles. ACS Nano. 2016;10(3):3015–41.
Zhang X, Huang G. Synthetic lipoprotein as nano-material vehicle in the targeted drug delivery. Drug Deliv. 2017;24(0):16–21.
Ma X, Song Q, Gao X. Reconstituted high-density lipoproteins: novel biomimetic nanocarriers for drug delivery. Acta Pharm Sin B. 2018;8(1):51–63.
Gupta A, Sharma R, Kuche K, Jain S. Exploring the therapeutic potential of the bioinspired reconstituted high density lipoprotein nanostructures. Int J Pharm. 2021;596:120272.
Mei Y, Tang L, Xiao Q, Zhang Z, Zhang Z, Zang J, et al. Reconstituted high density lipoprotein (rHDL), a versatile drug delivery nanoplatform for tumor targeted therapy. J Mater Chem B. 2021;9(3):612–33.
Fazel M, Daeihamed M, Osouli M, Almasi A, Haeri A, Dadashzadeh S. Preparation, in-vitro characterization and pharmacokinetic evaluation of brij decorated doxorubicin liposomes as a potential nanocarrier for cancer therapy. Iran J Pharm Res. 2018;17(Special Issue 2):33–43.
Rocha M, Chaves N, Báo S. Nanobiotechnology for Breast Cancer Treatment. In: Pham P Van, editor. Breast cancer – From Biology to Medicine. London, UK: IntechOpen; 2017. p. 13.
Gong M, Zhang Q, Zhao Q, Zheng J, Li Y, Wang S, et al. Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy. Drug Deliv. 2019;26(1):708–16.
Abed HN, Hussein AA. Ex-vivo absorption study of a novel dabigatran etexilate loaded nanostructured lipid carrier using non-everted intestinal sac model. Iraqi J Pharm Sci. 2019;28(2):37–45.
Bondarenko L, Terekhova V, Kahru A, Dzhardimalieva G, Kelbysheva E, Tropskaya N, et al. Sample preparation considerations for surface and crystalline properties and ecotoxicity of bare and silica-coated magnetite nanoparticles. RSC Adv. 2021;11:32227–35.
Raval N, Maheshwari R, Kalyane D, Youngren-Ortiz SR, Chougule MB, Tekade RK. Importance of physicochemical characterization of nanoparticles in pharmaceutical product development. Basic Fundamentals of Drug Delivery. Elsevier Inc.; 2018. 369–400 p.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Iraqi Journal of Pharmaceutical Sciences( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
This work is licensed under a Creative Commons Attribution 4.0 International License.
